Emcitate for MCT8 deficiency: FDA approval on September 28 covers peripheral thyrotoxicosis in adults and children. The evidence shows improvements in excess thyroid hormone and related cardiovascular and metabolic measures; the approval does not establish reversal of the disorder's severe neurological impairment.

Tempus ECG-MR: The company announced 510(k) clearance for AI software that reads 12-lead ECGs from eligible patients aged 65 and older and flags possible moderate or severe mitral regurgitation for further evaluation. A binary flag is not a valve diagnosis.

Link Cell LNK001: Clinical dosing has begun in a Phase 1 study of dual-antigen, logic-gated CAR-T for advanced clear cell renal cell carcinoma. Its Series A has grown by $30 million to $90 million in total; efficacy has not yet been demonstrated.

What we're watching next: US access and monitoring for Emcitate, prospective evidence and follow-up imaging after ECG-MR flags, and safety plus early tumor response in LNK001's dose-escalation study.

The FDA cites a randomized, placebo-controlled study and a longer-term open-label study. Across them, patients had lower excess thyroid hormone levels and improvements in measures such as heart rate and systolic blood pressure. The release does not claim restored neurological development.

The once-daily medicine is prepared as a liquid suspension and can be given orally or through a feeding tube. Common adverse reactions reported by FDA include diarrhea, vomiting, rash, and excessive sweating.

Egetis expects US commercial availability eight to ten weeks after approval and has set up a patient support program with PANTHERx Rare. That is a company forecast, not confirmation of availability or reimbursement. The FDA also granted a rare pediatric disease priority review voucher.

Mitral regurgitation is usually assessed with imaging such as echocardiography. ECG-MR can point clinicians toward further evaluation; it does not measure the leaking valve or establish a diagnosis.

The product is not for serial monitoring or paced ECGs. Tempus says results should be read alongside the original ECG, symptoms, history, and other tests.

The announcement provides no sensitivity, specificity, rollout date, site count, or prospective evidence that its alerts improve outcomes. Those are important adoption questions, rather than facts to infer from 510(k) clearance.

CAIX is found on many clear cell renal tumors, but also on some healthy tissue. The two-marker design aims to reduce unwanted activity in normal tissue. That selectivity is a design hypothesis awaiting human evidence.

MD Anderson describes two study parts: dose escalation to find a recommended dose, then dose expansion to assess disease control. The study is Phase 1 and enrolling; no response or safety outcomes were reported in the announcement.

Link says the extra financing will also support a planned colorectal cancer program, with a first-in-human trial intended for 2027. That program remains a plan.

Rare-disease access: When Emcitate reaches US specialty distribution, which patients are diagnosed and covered, and how will clinicians track thyroid and cardiovascular measures over time?

AI referral quality: What proportion of ECG-MR alerts leads to confirmatory echocardiography, and how many newly identified patients have care that changes as a result?

Solid-tumor CAR-T safety: Does LNK001 show the intended dual-antigen selectivity in dose escalation, and what early evidence of tumor control follows?

Link Cell Therapies: A $30 million extension increases its Series A from $60 million to $90 million. The money supports LNK001 and additional logic-gated programs. This is an expansion of one round, not a separate $90 million raise.

Sofinnova Partners: The firm announced an €82 million final close for MD Start IV, aiming to create six to eight medtech companies over five years. It is capital committed to a fund, not revenue or financing already received by those future companies.

TCT 2026: October 31–November 3, San Diego: interventional cardiology evidence and practice.

HLTH USA 2026: November 15–18, The Venetian Expo, Las Vegas: health systems, payers, technology, policy, and investment.

RSNA 2026: November 29–December 3, McCormick Place, Chicago: radiology research and technology.

Tempus ECG-MR: finding a reason to order an echo. The newly cleared software flags ECGs from a defined population aged 65 and older for possible undiagnosed moderate or severe mitral regurgitation. It produces a binary aid, not a diagnosis. Its practical metric is confirmed cases and appropriate follow-up after an alert, as covered in today's lead story.

CapsoVision AI Highlights: narrowing the capsule-video review. CapsoVision announced on September 28 that FDA clearance had been granted September 25 for its tool to mark suspected lesions in CapsoCam Plus small-bowel studies performed for suspected bleeding. It prioritizes images for a trained reader; it does not replace the physician's interpretation. Watch measured review time and missed-lesion performance in practice.

Physitrack EMR: the therapy visit becomes the record. Physitrack opened US early access on September 28 for small physical therapy practices. Its AI drafts visit notes and suggests home exercises for clinician approval. Physitrack says its security audit is still underway and it cannot yet sign a Business Associate Agreement for protected health information, so early access should not be read as clearance for live patient records.

Basalt Health: post-acute admissions. The Nashville startup announced a $20 million Series A on September 24 to expand software that reads referrals and checks them against facility criteria. At Lifepoint Health, Basalt reports that median chart-processing time fell from 8.5 to 1.2 minutes; that is a company-reported workflow measure, not evidence yet of fewer readmissions. The test now is whether faster processing reliably gets patients to suitable care.

Ferry Health: care navigation that makes the calls. Ferry emerged from stealth on September 16 with $9 million in seed funding. Its assistant searches for in-network providers, calls to confirm details and availability, and books appointments. The company says more than one million patients have access through partners; access is not the same as completed bookings or faster treatment. Watch appointment completion and how often staff must correct the agent.

Health Force: agents behind the hospital desk. The Barcelona company raised €4.2 million in seed funding on September 17 for AI agents handling insurance and administrative processes in European hospitals. Its investor says the platform supports work behind more than 200,000 patient cases annually; the open question is how those claims translate into audited accuracy, turnaround time, and staff oversight at more sites.

The MCT8 Treatment Boundary: What Emcitate's Approval Changes and What It Leaves Open: mechanism, clinical endpoints, daily delivery, and US access.

The ECG-to-Echo Pathway: Where Tempus ECG-MR Must Prove Its Value: cleared population, binary alert, confirmatory imaging, and implementation metrics.

The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis: AND-gate logic, trial design, financing, and the evidence that would change the thesis..